Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intra-Cellular Therapies (ITCI) stocks in Canada

Learn how to easily invest in Intra-Cellular Therapies stocks.

Intra-Cellular Therapies is a drug manufacturers-specialty & generic business based in the US. Intra-Cellular Therapies stocks (ITCI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $40.34 – a decrease of 9.75% over the previous week. Intra-Cellular Therapies employs 383 staff and has a trailing 12-month revenue of around $70.6 million.

How to buy shares in Intra-Cellular Therapies

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITCI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Intra-Cellular Therapies stock price (NASDAQ:ITCI)

Use our graph to track the performance of ITCI stocks over time.

Intra-Cellular Therapies shares at a glance

Information last updated 2022-01-17.
Latest market close$38.87
52-week range$28.40 - $55.20
50-day moving average $42.71
200-day moving average $38.22
Wall St. target price$60.89
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.20

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Intra-Cellular Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Intra-Cellular Therapies price performance over time

Historical closes compared with the close of $38.87 from 2022-01-20

1 week (2022-01-12) -2.14%
1 month (2021-12-17) N/A
3 months (2021-10-21) -9.37%
6 months (2021-07-21) 3.54%
1 year (2021-01-21) 18.92%
2 years (2020-01-21) 52.85%
3 years (2019-01-18) 209.72%
5 years (2017-01-20) 186.23%

Intra-Cellular Therapies financials

Revenue TTM $70.6 million
Gross profit TTM $-44,864,187
Return on assets TTM -24.56%
Return on equity TTM -43.32%
Profit margin 0%
Book value $5.98
Market capitalisation $4 billion

TTM: trailing 12 months

Intra-Cellular Therapies share dividends

We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.

Intra-Cellular Therapies share price volatility

Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $28.4 up to $55.195. A popular way to gauge a stock's volatility is its "beta".

ITCI.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.1429. This would suggest that Intra-Cellular Therapies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Intra-Cellular Therapies overview

Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site